

US FDA ACCEPTS REGULATORY SUBMISSION FOR ACALABRUTINIB AND GRANTS PRIORITY REVIEW

02 August 2017

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.

The NDA is based on results from the Phase II ACE-LY-004 clinical trial, which evaluated the safety and efficacy of acalabrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one prior therapy. This follows the FDA's [recent Breakthrough Therapy Designation](#) for acalabrutinib.

Sean Bohan, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: "FDA's acceptance of the acalabrutinib application and Priority Review illustrates the impact it could have on patients with relapsed or refractory mantle cell lymphoma as we work to bring this potential medicine to those in need as quickly as possible."

Priority Review is granted to applications for medicines that, if approved, would offer a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.ⁱ The Prescription Drug User Fee Act (PDUFA) date is during the first quarter of 2018.

Flavia Borellini, PhD, Acerta Pharma Chief Executive Officer, said: "We believe acalabrutinib has the potential to be a very important treatment option for patients with this life-threatening blood cancer. The FDA's NDA acceptance exemplifies our progress in the acalabrutinib development programme and continues our momentum as we seek to transform care for people with haematologic malignancies."

Results from the ACE-LY-004 clinical trial will be submitted for presentation at a forthcoming medical meeting. The acalabrutinib development programme includes both monotherapy and combination therapy strategies in a broad range of blood cancers and solid tumours. The programme includes the Phase III ACE-LY-308 clinical trial evaluating acalabrutinib as a 1st-line treatment for patients with MCL.ⁱⁱ

– ENDS –

NOTES TO EDITORS

About mantle cell lymphoma (MCL)

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.^{iii,iv,v,vi} MCL accounts for approximately 3% to 6% of new NHL cases in

News Release

Western countries each year, with an annual incidence of 0.5 per 100,000 persons and an estimated prevalence of 3.5/100,000.^{5,vii} The median age at diagnosis is 68 years, with a 3:1 male predominance.⁵

About acalabrutinib

Acalabrutinib is a highly-selective, potent, covalent inhibitor of Bruton tyrosine kinase (BTK) with minimal off-target activity observed in pre-clinical trials.^{viii,ix,x} This potential new medicine is in development for the treatment of multiple B-cell and other cancers. The acalabrutinib development programme includes both monotherapy and combination therapy strategies in chronic lymphocytic leukaemia (CLL), MCL, Waldenström macroglobulinemia (WM), follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma, as well as monotherapy and combination trials in solid tumours. In total, more than 25 acalabrutinib clinical trials with more than 2,000 patients are underway or have completed. Acalabrutinib was granted Orphan Drug Designation by the FDA for the treatment of patients with MCL in September 2015 and by the European Commission in March 2016 for the treatment of patients with CLL, MCL and WM. Acalabrutinib was granted Breakthrough Therapy Designation by the FDA in August 2017 for the treatment of patients with MCL who have received at least one prior therapy. Acalabrutinib is a potential new medicine not approved for any current use.

About Acerta Pharma

Acerta Pharma, a member of the AstraZeneca Group, is creating novel selective therapies intended for the treatment of cancer and autoimmune diseases. AstraZeneca acquired a majority stake in Acerta Pharma, which serves as AstraZeneca's haematology research and development centre of excellence. For more information, please visit www.acerta-pharma.com.

About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that have the potential to transform patients' lives and the Company's future. With at least six new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca's five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms -- Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates -- and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

| | | |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |

News Release

| | | |
|-----------------|-----------|------------------|
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

| | | |
|---------------------|---|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology | +1 240 477 3771 |
| Nick Stone | Respiratory, <i>Brilinta</i> | +44 203 749 5716 |
| Christer Gruvris | Diabetes; Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| US toll free | | +1 866 381 7277 |

References

ⁱ US Food and Drug Administration. Priority Review.

<https://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm> Accessed June 2017

ⁱⁱ Acerta Pharma BV. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from

<https://clinicaltrials.gov/ct2/show/NCT02972840?term=LY-308&cond=acalabrutinib&rank=1>

ⁱⁱⁱ Leukemia & Lymphoma Society. Mantle Cell Lymphoma Facts.

https://www.lls.org/sites/default/files/file_assets/mantlecellymphoma.pdf Accessed June 2017

^{iv} Cheah CY, Seymour JF, Wang M. Mantle Cell Lymphoma. *Journal of Clinical Oncology* 34, no. 11 (April 2016) 1256-1269.

^v Hoster E, Klapper W et al. Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. *Journal of Clinical Oncology* 2014;32:1338-1346.

^{vi} Dreyling M, Ferrero S. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? *Haematologica* 2016 Volume 101(2):104-114

^{vii} Orphanet Report Series. Prevalence and incidence of rare diseases: Bibliographic data. Number 2 March 2016.

^{viii} Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. *Cancer Res.* 2015;75(15 Supplement):2596.

^{ix} Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2016;374(4):323–32.

^x Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. *Blood.* 2015;126(23):2908.